Clinical laboratory最新文献

{"title":"A Peripheral Blood Circular Ribonucleic Acid-Based Nomogram for Risk Stratification in Chronic Myeloid Leukemia.","authors":"Yuanyuan Bai, Xiangjun Li, Yingying Wang, Zhanguo Chen","doi":"10.7754/Clin.Lab.2025.251027","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2025.251027","url":null,"abstract":"<p><strong>Background: </strong>Current prognostic tools for chronic myeloid leukemia (CML) rely primarily on clinical parameters and lack reliable molecular biomarkers for dynamic risk assessment. Circular RNAs (circRNAs) have emerged as promising liquid biopsy biomarkers because of their stability in peripheral blood. However, their prognostic value in CML remains underexplored.</p><p><strong>Methods: </strong>In this retrospective cohort study, peripheral blood samples were collected from 417 patients newly diagnosed with CML and 45 healthy controls. Differentially expressed circRNAs were identified by high-throughput sequencing and validated by quantitative real-time PCR. The patients were randomly divided into training (n = 292) and validation (n = 125) cohorts. A prognostic nomogram incorporating circRNAs and clinical variables was developed using multivariate Cox regression, with model performance assessed using the area under the curve (AUC), calibration, and decision curve analysis.</p><p><strong>Results: </strong>Two circRNAs (hsa_circ_0001523 and hsa_circ_0000095) were significantly dysregulated in patients with advanced-phase CML (p < 0.0001). The nomogram combining the expression patterns of two circRNAs with basophil%, blast%, and hemoglobin levels achieved an AUC of 0.920 (95% CI: 0.873 - 0.968) for survival prediction. High-risk patients (score > 122.5) had a significantly shorter median survival (22 vs. 83 months, p < 0.0001).</p><p><strong>Conclusions: </strong>This circRNA-based nomogram is a clinically applicable, non-invasive tool for dynamic risk stratification in CML. The integration of molecular and hematological markers may guide personalized therapy decisions and address the limitations of existing prognostic systems.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"72 10","pages":"2233-2242"},"PeriodicalIF":0.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in Biomarkers for Muscular Dystrophies: a Comprehensive Review.","authors":"Li Hou","doi":"10.7754/Clin.Lab.2025.251112","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2025.251112","url":null,"abstract":"<p><strong>Background: </strong>Muscular dystrophies (MDs) are a group of genetically heterogeneous diseases characterized by progressive muscle degeneration and functional impairment. Current treatment options remain limited, highlighting the urgent need for biomarkers to enhance diagnosis, monitor disease progression, and evaluate treatment efficacy across different subtypes, such as Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), facioscapulohumeral muscular dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD).</p><p><strong>Methods: </strong>A search of the MEDLINE/PubMed databases was conducted for original and review articles that examined biomarkers associated with muscular dystrophies. Based on the findings from these articles, a comprehensive review was constructed.</p><p><strong>Results: </strong>The study identified significant advancements in various categories of biomarkers, including protein biomarkers, microRNA profiles, imaging parameters, functional assessments, as well as emerging fields such as extracellular vesicles and epigenetic modifications.</p><p><strong>Conclusions: </strong>Research on biomarkers in muscular dystrophies has evolved from a focus on single biomarkers to a comprehensive multiomics approach. Future research directions should emphasize multicenter validation and the development of biomarker-guided therapeutic strategies to advance the application of personalized medicine in muscular dystrophies.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"72 10","pages":"2057-2064"},"PeriodicalIF":0.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Value of MiR-934 and MiR-1260a in Plasma and Early Detection of Metastasis in Patients with Cervical Cancer.","authors":"Li-Fang Zheng, Jun Qian, Yu-Fang Song","doi":"10.7754/Clin.Lab.2025.250353","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2025.250353","url":null,"abstract":"<p><strong>Background: </strong>This study investigated miR-934 and miR-1260a expression in the plasma of patients with cervical cancer (CC) and their prognostic values.</p><p><strong>Methods: </strong>miR-934 and miR-1260a in the plasma of 100 CC patients, 45 patients with cervical intraepithelial neoplasia (CIN), and healthy subjects were detected by RT-qPCR method, and the relationship between miR-934 and miR-1260a expression with clinicopathological characteristics of CC patients was analyzed. Kaplan-Meier and COX hazard regression models were constructed to analyze the prognostic value of miR-934 and miR-1260a in CC.</p><p><strong>Results: </strong>miR-934 and miR-1260a levels in CC patients were higher than in CIN patients and healthy subjects. Patients exhibiting high levels of miR-934 and miR-1260a experienced shorter progression-free and overall survival than those with lower levels. Clinical stage, lymph node metastasis, depth of invasion, and high miR-934 and miR-1260a were influencing factors of CC patients' prognosis.</p><p><strong>Conclusions: </strong>Plasma miR-934 and miR-1260a are closely related to the clinicopathological features and prognosis of CC patients and may be potential markers to predict CC prognosis.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"72 10","pages":"2065-2074"},"PeriodicalIF":0.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149134824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Values of Blood Coagulation Parameters in Distinguishing Esophagogastric Variceal Bleeding from Peptic Ulcer Bleeding.","authors":"Tian-Ran Li, Meng-Di Zhang, Xu Gong, Hai-Xia Song, Ju Jiang, Yue-Zhan Zhang","doi":"10.7754/Clin.Lab.2025.251044","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2025.251044","url":null,"abstract":"<p><strong>Background: </strong>Esophagogastric variceal bleeding (EGVB), manifested with similar symptoms of hematemesis and/ or melaena, is often difficult to differentiate from peptic ulcer bleeding (PUB). It remains unclear whether blood coagulation parameters can be used to distinguish between EGVB and PUB.</p><p><strong>Methods: </strong>A total of 37 EGVB patients (EGVB group) and 89 cases with PUB (PUB group), were enrolled for final analysis retrospectively. The levels of coagulation parameters, including prothrombin time (PT), activated partial thromboplastin time (APTT), Fibrinogen, and D-dimer, were tested in the emergency department and compared between the two groups. Student's t-test was adopted for comparing the mean. Model discrimination was evaluated by using the area under the receiver operating characteristic curve (AUC).</p><p><strong>Results: </strong>Compared with PUB group, PT, APTT, and D-dimer were significantly increased, while fibrinogen was significantly decreased in EGVB group (all p < 0.01); moreover, binary logistic regression analysis adjusted for covariate showed that PT, APTT, fibrinogen, and D-dimer remained independent risk factors for predicting EGVB; next, the AUC in distinguishing EGVB from PUB were 0.843, 0.725, 0.766, and 0.821 for PT, APTT, fibrinogen, and D-dimer, respectively; finally, the cutoff values (specificity, sensitivity, and Youden index) in distinguishing EGVB from PUB were 12.9 s (80.9%, 78.4%, 0.593) for PT, 25.1 s (68.5%, 78.4%, 0.469) for APTT, 1.99 g/L (67.4%, 75.7%, 0.431) for fibrinogen, and 0.31 mg/L (75.3%, 78.4%, 0.537) for D-dimer, respectively.</p><p><strong>Conclusions: </strong>PT, APTT, fibrinogen, and D-dimer, useful and potential biomarkers in distinguishing EGVB from PUB, can demonstrate accurate and reliable diagnostic values.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"72 10","pages":"2262-2268"},"PeriodicalIF":0.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Novel GNN-Bi-LSTM Framework with Attention Mechanism for Detecting Rare Genetic Disorders.","authors":"Osama R Shahin, Raed N Alabdali, Mohamed N Ibrahim, Wael Alzahrani, Eman Fawzy El Azab, Eman Elsayed Bauomey Mohamed","doi":"10.7754/Clin.Lab.2025.250934","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2025.250934","url":null,"abstract":"<p><strong>Background: </strong>The growing population in the world and inadequate health care guidelines have caused the onset of sporadic genetic disorders that need effective diagnostic and prognostic methods. However, the existing systems cannot handle the multisystem nature of genetic information resulting in delays of formal identification and therapeutic procedures.</p><p><strong>Methods: </strong>The proposed study aims at proposing a more reliable model, GNN-Bi-LSTM-AM, that incorporates Graph Neural Networks (GNN), Bi-LSTM, and attention module to improve the process of identifying and diagnosing rare genetic disorders (RGDs). In this model, GNN is used to describe the genetic factors' associations with other factors, whereas Bi-LSTM models the health data over time. The attention mechanism puts emphasis on sig-nificant genetic markers, which improves predictive ability and minimizes interpretation challenges. The framework makes use of complex data such as maternal health history and parental genetic inheritance. In particular, the GNN learns the association between patients on the basis of genetic similarities, and Bi-LSTM computes temporal details of health information, and the attention module is applied to pay attention to important elements.</p><p><strong>Results: </strong>The results of the experiment show that the proposed GNN-Bi-LSTM-AM model predicts the accuracy of 98.5, precision of 96, recall of 96, and an F1-score of 96, which is much better than traditional machine learning methods. The framework has also good efficiency in that the processing time was 7.85 seconds.</p><p><strong>Conclusions: </strong>The GNN-Bi-LSTM-AM framework suggested is a great step towards predictive analytics of rare genetic diseases. The model can be used to provide promising applications in early detection and clinical diagnosis by combining genetic relationships, sequential health data, and feature relevancy. Therefore, it is practical in enhancing treatment interventions and patient outcomes in genetic medicine.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"72 10","pages":"2164-2178"},"PeriodicalIF":0.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HALP Score as a Mortality Predictor in Elderly Home-Care Patients.","authors":"Yasin Altun, Aysima B Acar, Halime D Balci, Başak O Yolcular","doi":"10.7754/Clin.Lab.2025.251028","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2025.251028","url":null,"abstract":"<p><strong>Background: </strong>The hemoglobin, albumin, lymphocyte, and platelet (HALP) scoring system reflects nutritional status and systemic inflammation and aims to provide information about patients' prognosis. This study aims to eval-uate the association between the HALP score and mortality risk in elderly home-care patients.</p><p><strong>Methods: </strong>This retrospective study included 481 elderly patients who died between January 2021 and December 2023 while being followed by the Home Health Care Service. The dates of death were recorded, and survival durations were categorized into groups. Laboratory parameters obtained from hospital electronic records were used to calculate HALP scores (hemoglobin x albumin x lymphocyte)/platelet. Additionally, neutrophil-to-lymphocyte ratio (NLR) and C-reactive protein-to-albumin ratio (CAR) were calculated for comparison. Statistical analyses included ROC curve analysis, correlation tests, and group comparisons based on survival duration.</p><p><strong>Results: </strong>A HALP score cutoff of ≤ 25.22 predicted mortality with a sensitivity of 68.27% and specificity of 53.68%. Both NLR and CAR were inversely correlated to survival times (p < 0.05). Patients with longer survival durations had significantly higher HALP scores and lower NLR and CAR values compared to those with shorter survival durations.</p><p><strong>Conclusions: </strong>The HALP and modified HALP may serve as useful prognostic markers for mortality prediction in elderly home-care patients. Since HALP is calculated from simple, routinely available laboratory parameters, its use in home health care settings-where geriatric and multimorbid patients predominate-could contribute to early risk stratification and cost-effective care planning.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"72 10","pages":"2243-2250"},"PeriodicalIF":0.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Detection of BRCA1 and BRCA2 Mutations in Saudi Females with Breast Cancer in Al-Madinah Province by Next Generation Sequencing.","authors":"Osama Abdulaziz","doi":"10.7754/Clin.Lab.2025.250602","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2025.250602","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer has the highest incidence among Saudi women and is often diagnosed at a younger age with distinct genetic features. This study aimed to determine the prevalence and mutation of germline BRCA1 and BRCA2 mutations in Saudi women in Al-Madinah Province with breast cancer.</p><p><strong>Methods: </strong>This cross-sectional study included 54 Saudi females with a median age of 46.5 years (IQR 39.0 - 53.7 years). Genomic DNA from peripheral blood was screened using high-depth next-generation sequencing (NGS), which encompassed all coding exons and splice regions of BRCA1 and BRCA2. Variants were classified according to the American College of Medical Genetics and Genomics (ACMG) guidelines. Clinical information, such as age at diagnosis, cancer subtype, staging, treatment response, and overall survival, was collected from patients' medical files to assess them against mutation status.</p><p><strong>Results: </strong>Pathogenic or likely pathogenic BRCA variants were found in eight patients (14.8%): five had BRCA1 mutations (62.5%), four of which were pathogenic variants including a large exon 16 deletion in one patient and one was likely a pathogenic variant. Three patients had BRCA2 mutations (37.5%); all of which were pathogenic variants. Most mutation carriers (62.5%) developed the disease at a relatively young age, particularly in BRCA2 carrier ER-positive patients, although the difference between carriers and non-carriers was not statistically significant (p = 0.6). Carriers were significantly more likely to have a positive family history (p = 0.001). The mortality rate was higher in carriers (25%) than in non-carriers (2.2%); however, this difference was statistically non-significant (p = 0.05), a finding that may be related to the small sample size.</p><p><strong>Conclusions: </strong>Mutations of BRCA1 and BRCA2 were detected; the prevalence was 14.8%. These mutations are associated with a relatively young age at diagnosis, a positive family history, and a lower survival rate. The findings highlight the need for robust BRCA mutation screening and genetic counseling for female breast cancer patients to enable appropriate risk assessment and clinical intervention.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"72 10","pages":"2075-2082"},"PeriodicalIF":0.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149134976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-Linear U-Shaped Trend Associations between HbA1c and All-Cause and Cardiovascular Mortality.","authors":"Fengquan Shi, Kaiqiang Xi","doi":"10.7754/Clin.Lab.2025.251013","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2025.251013","url":null,"abstract":"<p><strong>Background: </strong>Several well-designed prospective studies have assessed the association between glycated hemoglobin (HbA1c) and mortality risk in both the general population and diabetic patients. However, the results have been inconsistent.</p><p><strong>Methods: </strong>We conducted a prospective study using data from NHANES 2003 - 2018, which included 38,072 adults. Cox proportional hazards regression and restricted cubic spline models were used to evaluate the linear and non-linear associations between HbA1c and both all-cause mortality and cause-specific mortality. To better detect non-linear relationships, we converted HbA1c from a continuous to a categorical variable. Kaplan-Meier survival cur-ves and subgroup analyses were also performed.</p><p><strong>Results: </strong>During an average follow-up period of 99.7 ± 53.6 months, 4,723 participants (12.4%) died. We observed a significant non-linear U-shaped association between baseline HbA1c levels and mortality. Compared with a moderate HbA1c level of 5.5%, the risk of all-cause and cause-specific mortality decreased for HbA1c values below 5.5%. However, mortality risk significantly increased for HbA1c levels above 5.5%. This indicates that individuals with either low or high HbA1c levels are at a higher risk of all-cause mortality. Additionally, we identified an L-shaped trend in cancer mortality.</p><p><strong>Conclusions: </strong>We demonstrated a U-shaped association between baseline HbA1c levels and all-cause mortality in the general population. Individuals with both low and high HbA1c levels are at a greater risk of all-cause mortality. Future clinical trials on diabetes management should consider the consequences of lower HbA1c levels, especially across different populations.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"72 10","pages":"2211-2220"},"PeriodicalIF":0.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149134686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection of Serum IL-1β and IL-10 as Biomarkers for Anti-Tuberculosis Drug Resistance.","authors":"Ya Yang, YongSheng Ji, LiYang Wang, ShouHua Xu, YongQian Jiang, YingLing Zhu, XueBin Qu, YouGen Luo, LiuCai Yang, XiangJun Zhu","doi":"10.7754/Clin.Lab.2025.250825","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2025.250825","url":null,"abstract":"<p><strong>Background: </strong>To investigate the levels of cytokines (IL-1β, IL-2R, IL-6, IL-8, IL-10, TNF-α, IFN-γ) in tuberculosis (TB) patients with different clinical characteristics (sputum smear status, cavity presence, lesion extent, Mycobacterium type, and drug resistance) and explore their clinical significance.</p><p><strong>Methods: </strong>A total of 258 active TB patients (divided into drug-resistant and non-drug-resistant groups) and 62 quiescent TB controls were enrolled. Serum cytokine levels were detected by ELISA.</p><p><strong>Results: </strong>Serum IL-1β, sIL-2R, IL-6, IL-10, TNF-α, and IFN-γ were significantly higher in active TB patients than in controls (all p < 0.01), while IL-8 showed no difference. IL-1β levels were notably higher in drug-resistant vs. non-drug-resistant patients (p < 0.01). In subgroups with positive sputum smear, extensive lesions, cavity formation, or bovine TB infection, IL-1β and IL-10 levels increased with disease severity. IL-1β was significantly elevated in streptomycin (SM)-resistant, rifampicin (RFP)-resistant, and related combined drug-resistant subgroups (p < 0.01/0.05).</p><p><strong>Conclusions: </strong>Serum IL-1β in combination with IL-10 may serve as a marker for evaluating TB activity, lesion progression, and bacillary type, while IL-1β alone could indicate partial drug resistance (e.g., to SM, RFP, and related combinations).</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"72 10","pages":"2097-2108"},"PeriodicalIF":0.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adropin as a Novel Biomarker in the Diagnosis of Acute Pulmonary Embolism: a Prospective Analysis.","authors":"B Gulen, H İ Celik, G Bozkus, Y Ugurlu, A Kocyigit","doi":"10.7754/Clin.Lab.2025.251024","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2025.251024","url":null,"abstract":"<p><strong>Background: </strong>Pulmonary embolism (PE) is a potentially life-threatening condition requiring rapid diagnosis and management. While computed tomography pulmonary angiography (CTPA) is the gold standard for diagnosis, its overuse raises concerns about radiation exposure and healthcare costs. The objective of this study was to evaluate the diagnostic performance of serum adropin (ADR) levels in patients presenting to the emergency department with suspected acute PE.</p><p><strong>Methods: </strong>This prospective, cross-sectional study included 120 patients who underwent CTPA due to suspected PE. Serum ADR levels were measured using ELISA. Patients were stratified by Wells score into low, moderate, and high-risk groups. Receiver operating characteristic (ROC) analysis was used to determine the diagnostic accuracy of ADR for predicting PE.</p><p><strong>Results: </strong>Of the 120 patients, 40% had confirmed PE (n = 48) of patients. Median ADR levels were lower in patients with PE than in those without PTE (419, IQR: 270 - 512 vs. 481.6, IQR: 375 - 606, respectively; p = 0.03). This was also true for patients with chronic disease when compared to patients without chronic disease (413, IQR: 264 - 534 vs. 500, IQR: 433 - 685, respectively; p = 0.01). ROC analysis revealed an AUC value of 0.612 (95% CI: 0.510 - 0.714; p = 0.032) for ADR in diagnosing PE.</p><p><strong>Conclusions: </strong>While ADR alone is insufficient as a primary diagnostic tool for PE, it may serve as a complementary biomarker particularly in D-dimer positive patients with low clinical probability at specific cutoff values. However, prospective studies are warranted to validate this approach.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"72 10","pages":"2226-2232"},"PeriodicalIF":0.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}